4.5 Article

Combination treatment with VPA and MSCs-TRAIL could increase anti-tumor effects against intracranial glioma

Journal

ONCOLOGY REPORTS
Volume 45, Issue 3, Pages 869-878

Publisher

SPANDIDOS PUBL LTD
DOI: 10.3892/or.2021.7937

Keywords

GBM; VPA; MSCs-TRAIL; CXCR4; SDF-1

Categories

Funding

  1. Ministry of Health and Welfare, Republic of Korea [HI18C2148]
  2. Basic Science Research Program through the National Research Foundation of Korea - Ministry of Education [2016R1D1A1B03931146]
  3. National Research Foundation of Korea [2016R1D1A1B03931146] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)

Ask authors/readers for more resources

This study examined the synergistic effect of valproic acid (VPA) in enhancing MSC-delivered TRAIL efficacy, as well as the induced tumor tropism of MSCs. Combination treatment with VPA and MSCs-TRAIL increased therapeutic effect against glioma by enhancing death receptor 5 and caspase activation. Migration assays showed increased MSC migration in glioma cells and tumor site in glioma-bearing mice when treated with VPA and MSCs-TRAIL. In vivo experiments demonstrated greater therapeutic efficacy when MSC-based TRAIL gene delivery was used in VPA-treated tumors compared to each agent alone.
Human bone marrow-derived mesenchymal stem cells secreting tumor necrosis factor-related apoptosis-inducing ligand (MSCs-TRAIL) have demonstrated effective anti-tumor activity against various tumors including lung, pancreatic and prostate tumors, although several tumor types are not responsive. In such case, other reagents may decrease tumor growth via TRAIL-mediated cell death. The present study aimed to examine the effectiveness of valproic acid (VPA) in enhancing the efficacy of TRAIL, which was delivered using MSCs. Moreover, the present study examined the induced tumor tropism of MSCs via cell viability and migration assays. Combination treatment with VPA and MSCs-TRAIL enhanced the glioma therapeutic effect by increasing death receptor 5 and caspase activation. Migration assays identified increased MSC migration in VPA and MSCs-TRAIL-treated glioma cells and in the tumor site in glioma-bearing mice compared with VPA or MSC-TRAIL treatment alone. In vivo experiments demonstrated that MSC-based TRAIL gene delivery to VPA-treated tumors had greater therapeutic efficacy compared with treatment with each agent alone. These findings suggested that VPA treatment increased the therapeutic efficacy of MSC-TRAIL via TRAIL-induced apoptosis and enhanced tropism of MSCs, which may offer a useful strategy for tumor gene therapy.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available